A long-simmering dispute between Eli Lilly and Co. and safety-net hospitals across the nation over the price of prescription drugs has reached the boiling point.
It’s a big pivot for organizations that traditionally create high-visibility fall projects to call attention to volunteerism and community service. In the process, they help dozens of neighborhood groups and scores of not-for-profits, from the United Way of Central Indiana to Keep Indianapolis Beautiful.
For Indy’s employers—large and small—to remain strong, they need a working environment in which the most innovative ideas and strongest strategies emerge, and we believe for most firms, that’s tough to accomplish in a remote work environment.
A drug company said Friday that a medicine it sells to tamp down inflammation has helped prevent the need for breathing machines in hospitalized COVID-19 patients.
The medical school said it is testing the use of tezampanel, an experimental drug for migraines developed by Indianapolis-based drugmaker Eli Lilly and Co., to treat opioid withdrawal syndrome and other addictions and mental illnesses.
Wednesday’s results come from 450 people in a mid-stage study testing an antibody jointly developed by Lilly and the Canadian company AbCellera in people with COVID-19 symptoms not severe enough to warrant hospitalization.
Lilly and partner Boehringer Ingelheim published results from a trial showing the drug cut the risk of cardiovascular hospitalizations or death by 25%, compared to placebo in heart failure patients.
So far, Elanco has been a textbook case for the benefits of spinoffs—for both the parent company divesting the business and the division gaining its independence.
In 2018, only about 7% of childhood flu shots were administered at pharmacies, according to CDC data. And it’s even rarer for other childhood shots to be given at drug stores.
Adams, the senior vice president of product engineering at Jobvite, has led the company’s recent advancements on the artificial intelligence front with machine learning and sentiment analysis, as well as analytics.
People with disabilities are unemployed and underemployed to a greater extent than their able-bodied peers and face lower wages, misunderstanding and limitations on their earning capacity if they must rely on essential things such as attendant care.
With a coronavirus vaccine still months off, companies—including Indianapolis-based Eli Lilly and Co.—are rushing to test what might be the next best thing: drugs that deliver antibodies to fight the virus.
Now that the company has closed its $6.9 billion acquisition of the German conglomerate’s animal-health division, it must now swiftly and carefully integrate the two sprawling companies in the midst of a pandemic.
About 60 entertainment stages, bars and studios across Indiana have joined forces in a new association to fight for government assistance they say is needed to survive.
The newly formed Indianapolis African American Quality of Life Renewal Initiative will seek to encourage collaboration and resource sharing between public, private and civic institutions.
The Indianapolis-based drugmaker said it will enroll about 2,400 residents and staff of nursing homes to test an antibody it is developing with a Canadian biotech. Nursing homes account for about 40% of U.S. deaths from COVID-19.
An experimental blood test from Indianapolis-based Eli Lilly and Co. was highly accurate at distinguishing people with Alzheimer’s disease from those without it in several studies, boosting hopes that there soon may be a simple way to help diagnose the condition.
Under the agreement, researchers will study patients who used Lilly autoimmune therapies that are under consideration for the treatment of other autoimmune diseases, including inflammatory bowel disease and psoriasis.
